Navigate this market better. Subscribe for FREE stock alerts and information.

Tuesday, April 2, 2013

CORRECTED-Obagi Medical gets higher offer from Merz Pharma, (NASDAQ: OMPI), (NYSE: VRX), (TSE: VRX.TO)

Neurological and dermatology drugs maker Merz Pharma Group offered to purchase cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada's Valeant Pharmaceuticals International Inc last month.

Obagi Medical Products, Inc. (Obagi) is a specialty pharmaceutical company that develops, markets and sells, and is a provider of, topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Shares of OMPI remained unchanged at $19.71. In the past year, the shares have traded as low as $10.70 and as high as $19.90. On average, 451877 shares of OMPI exchange hands on a given day and today's volume is recorded at 243512.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $76.05. In the past year, the shares have traded as low as $42.47 and as high as $76.44. On average, 1321390 shares of VRX exchange hands on a given day and today's volume is recorded at 1450.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 1.39% or $1.06/share to $77.32. In the past year, the shares have traded as low as $43.99 and as high as $77.66. On average, 427342 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 0.



Source